Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 25, 2026

2 ETFs to Buy With $100 and Hold Forever

View original at finance.yahoo.com
2 ETFs to Buy With $100 and Hold Forever The stock market has already taken investors for a ride in 2026. After a relatively calm first two months of the year, the S&P 500 fell 9% only to turn around and bounce 12% higher off the lows…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Companies that grow steadily over time usually perform the best, better than high-growth speculative plays.

    60% confidence
  • VTI covers the entire U.S. equity market and makes sense as a core portfolio position.

    60% confidence
  • SCHD has a year-to-date return of 12.8%, the best among U.S. dividend ETFs.

    60% confidence
  • Investing in undervalued companies provides above-average returns over the long term if that value is unlocked, and value stocks also provide downside protection in falling markets.

    60% confidence
  • SCHD is one of the most popular dividend ETFs.

    60% confidence
  • The Indispensable Monopoly company provides the critical technology that both Nvidia and Intel need.

    60% confidence
  • AI could create the world's first trillionaire.

    60% confidence
  • Adding SCHD around a core VTI position adds an element of income growth and durability that can enhance long-term total returns.

    60% confidence
  • SCHD's strategy targets stocks that represent the best combination of balance sheet quality, dividend growth, and high yield.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com